maltose 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1628 69-79-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • maltose
  • D-Maltose
  • maltobiose
A dextrodisaccharide from malt and starch. It is used as a sweetening agent and fermentable intermediate in brewing. (Grant & Hackh's Chemical Dictionary, 5th ed)
  • Molecular weight: 342.30
  • Formula: C12H22O11
  • CLOGP: -4.40
  • LIPINSKI: 2
  • HAC: 11
  • HDO: 8
  • TPSA: 189.53
  • ALOGS: 0.23
  • ROTB: 4

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.293 Moderate 0.77
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.612 Moderate 0.77
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.435 10^-6 cm/s Moderate 0.77
dh-clint Dog hepatocyte intrinsic clearance 1.175 uL/min/10^6 cells Moderate 0.77
dppb Dog plasma protein binding (% unbound) 84.510 % Moderate 0.77
fcs-ppb Fetal calf serum protein binding (% unbound) 88.140 % Moderate 0.77
herg hERG pIC50 3.906 pIC50 Moderate 0.77
hh-clint Human hepatocyte intrinsic clearance 0.773 uL/min/10^6 cells Moderate 0.77
hlm-clint Human liver microsomal intrinsic clearance 3.499 uL/min/mg protein Moderate 0.77
hppb Human plasma protein binding (% unbound) 77.660 % Moderate 0.77
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PIK3CD,PRKDC,SIK2,STK33,TEK 27
kinase-selectivity-class ACVRL1,CHUK,MAP2K6,PDK1,PIK3CD,ZAP70 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.570 Moderate 0.77
mh-clint Mouse hepatocyte intrinsic clearance 0.714 Moderate 0.77
mppb Mouse plasma protein binding (% unbound) 89.640 Moderate 0.77
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.624 Moderate 0.77
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 92.580 % Moderate 0.77
rh-clint Rat hepatocyte intrinsic clearance 3.020 uL/min/10^6 cells Moderate 0.77
rh-fuinc Rat hepatocyte fraction unbound in incubation 94.270 % Moderate 0.77
rppb Rat plasma protein binding (% unbound) 87.220 % Moderate 0.77
solubility-dd Solubility at pH 7.4 in DMSO 907.821 uM Moderate 0.77

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 202.50 182.37 69 4324 13387 42603555
Myasthenia gravis 201.52 182.37 72 4321 16065 42600877
Hyperphosphataemia 189.10 182.37 65 4328 12939 42604003

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 262.62 156.98 69 4380 14186 110570664
Myasthenia gravis 247.77 156.98 72 4377 21439 110563411
Hyperphosphataemia 234.57 156.98 65 4384 16316 110568534
Blood phosphorus increased 216.42 156.98 61 4388 16279 110568571
Appendicitis 215.47 156.98 69 4380 28395 110556455
Ventricular fibrillation 186.54 156.98 68 4381 41245 110543605
Hypophosphataemia 185.46 156.98 64 4385 33118 110551732
Neuralgia 172.39 156.98 67 4382 48411 110536439
Stress 171.84 156.98 84 4365 105264 110479586
Bacterial infection 168.58 156.98 65 4384 45971 110538879
Analgesic therapy 167.03 156.98 42 4407 7242 110577608
Drug therapy 162.02 156.98 41 4408 7250 110577600
Sleep disorder therapy 161.03 156.98 41 4408 7430 110577420

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D005421 Flavoring Agents
MeSH PA D005503 Food Additives
MeSH PA D013549 Sweetening Agents
CHEBI has role CHEBI:50505 sweetening agent
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:75772 <em>Saccharomyces cerevisiae </em> metabolite
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:77746 human metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.33 acidic
pKa2 13.14 acidic
pKa3 13.68 acidic
pKa4 13.99 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018046 VUID
N0000022443 NUI
D00044 KEGG_DRUG
4018046 VANDF
C0024658 UMLSCUI
CHEBI:17306 CHEBI
MAL PDB_CHEM_ID
CHEMBL1908365 ChEMBL_ID
DB03323 DRUGBANK_ID
D008320 MESH_DESCRIPTOR_UI
439186 PUBCHEM_CID
1311261 RXNORM
005153 NDDF
43431002 SNOMEDCT_US
R4B6462NGR UNII

Pharmaceutical products:

None